Weight loss drug developer Kailera Therapeutics (KLRA) and Alamar Biosciences (ALMR), a commercial-stage proteomics company, filed for their respective U.S. initial public offerings with the SEC on Friday.

Waltham, Massachusetts-based Kailera (KLRA), which has four GLP-1 candidates in the